D
Dominik Heim
Researcher at University Hospital of Basel
Publications - 191
Citations - 6163
Dominik Heim is an academic researcher from University Hospital of Basel. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 34, co-authored 163 publications receiving 5388 citations. Previous affiliations of Dominik Heim include University of Basel.
Papers
More filters
Journal ArticleDOI
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
Jürgen Finke,Wolfgang Bethge,Claudia Schmoor,Hellmut Ottinger,Matthias Stelljes,Axel R. Zander,Liisa Volin,Tapani Ruutu,Dominik Heim,Rainer Schwerdtfeger,Karin Kolbe,Jiri Mayer,Johan Maertens,Werner Linkesch,Ernst Holler,Vladimir Koza,Martin Bornhäuser,Hermann Einsele,Hans-Jochem Kolb,Hartmut Bertz,Matthias Egger,Olga Grishina,Gérard Socié +22 more
TL;DR: The addition of ATG-F to GVHD prophylaxis with ciclosporin and methotrexate resulted in decreased incidence of acute and chronic GV HD without an increase in relapse or non-relapse mortality, and without compromising overall survival.
Journal ArticleDOI
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
François Guilhot,Jane F. Apperley,Dong-Wook Kim,Eduardo Bullorsky,Michele Baccarani,Gail J. Roboz,Sergio Amadori,Carmino Antonio De Souza,Jeffrey H. Lipton,Andreas Hochhaus,Dominik Heim,Richard A. Larson,Susan Branford,Martin C. Müller,Prasheen Agarwal,Ashwin Gollerkeri,Moshe Talpaz +16 more
TL;DR: Dasatinib as discussed by the authors is a novel, potent, oral, multitargeted kinase inhibitor of BCR-ABL and SRC-family kinases that showed marked efficacy in a phase 1 trial of patients with imatinib-resistant CML.
Journal ArticleDOI
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
Rüdiger Hehlmann,Martin C. Müller,Michael Lauseker,Benjamin Hanfstein,Alice Fabarius,Annette Schreiber,Ulrike Proetel,Nadine Pletsch,Markus Pfirrmann,Claudia Haferlach,Susanne Schnittger,H. Einsele,Jolanta Dengler,Christiane Falge,Lothar Kanz,Andreas Neubauer,Michael Kneba,Frank Stegelmann,Michael Pfreundschuh,Cornelius F. Waller,Karsten Spiekermann,Gabriela M. Baerlocher,Gerhard Ehninger,Dominik Heim,Hermann Heimpel,Christoph Nerl,Stefan W. Krause,Dieter K. Hossfeld,Hans-Jochem Kolb,Joerg Hasford,Susanne Saußele,Andreas Hochhaus +31 more
TL;DR: MR(4.5) is a new molecular predictor of long-term outcome, is reached by a majority of patients treated with imatinib, and is achieved more quickly with optimized high-dose imatin ib, which may provide an improved therapeutic basis for treatment discontinuation in CML.
Journal ArticleDOI
Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.
Gérard Socié,Claudia Schmoor,Wolfgang Bethge,Hellmut Ottinger,Matthias Stelljes,Axel R. Zander,Liisa Volin,Tapani Ruutu,Dominik Heim,Rainer Schwerdtfeger,Karin Kolbe,Jiri Mayer,Johan Maertens,Werner Linkesch,Ernst Holler,Vladimir Koza,Martin Bornhäuser,Hermann Einsele,Hans-Jochem Kolb,Hartmut Bertz,Matthias Egger,Olga Grishina,Jürgen Finke +22 more
TL;DR: The addition of ATG-F to standard cyclosporine, methotrexate GVHD prophylaxis lowers the incidence and severity of cGVHD, and the risk of receiving IST without raising the relapse rate.
Journal ArticleDOI
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.
Sébastien Maury,Sylvie Chevret,Xavier Thomas,Dominik Heim,Thibaut Leguay,Françoise Huguet,Patrice Chevallier,Mathilde Hunault,Nicolas Boissel,Martine Escoffre-Barbe,Urs Hess,Norbert Vey,Jean-Michel Pignon,Thorsten Braun,Jean-Pierre Marolleau,Jean-Yves Cahn,Yves Chalandon,Véronique Lhéritier,Kheira Beldjord,Marie C. Béné,Norbert Ifrah,Hervé Dombret +21 more
TL;DR: Adding rituximab to the ALL chemotherapy protocol improved the outcome for younger adults with CD20-positive, Ph-negative ALL.